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Abstract
Purpose—To determine the predictive value of ophthalmic screening tests with visually 
significant eye disease in a cohort of American Indian/Alaskan Natives from the Pacific 
Northwest.
Design—Validity assessment of a possible screening protocol.
Methods—Ophthalmic technicians performed a screening examination including medical and 
ocular history, best-corrected visual acuity, limbal anterior chamber depth assessment, frequency 
doubling technology perimetry (FDT, C-20-5), confocal scanning laser ophthalmoscopy, 
nonmydriatic digital photography, and tonometry on 429 participants. An ophthalmologist 
performed a comprehensive eye exam on subjects with one or more abnormal screening tests and a 
random selection of those with normal screening tests. We used univariate and multivariate logistic 
regression to determine the association between abnormal screening test results and visually 
significant eye disease. We also determined the predictive value of screening tests with ocular 
disease.
Results—Univariate analysis identified history of eye disease or diabetes mellitus (p<.001), 
visual acuity <20/40 (p<.001), abnormal/poor quality confocal scanning laser ophthalmoscopy 
(p<.001), abnormal FDT (p<.001), and abnormal/poor quality non-mydriatic imaging (p<.001) as 
associated with visually significant eye disease. A multivariate analysis found visually significant 
eye disease to be associated (p<.001; receiver operating curve area= .827, negative predictive 
value=84%) with four screening tests: visual acuity <20/40, abnormal/poor quality non-mydriatic 
imaging, abnormal FDT and abnormal/poor quality confocal scanning laser ophthalmoscopy.
Conclusions—Ophthalmic technicians performing a subset of screening tests may provide an 
accurate and efficient means of screening for eye disease in an American Indian/Alaskan Native 
population. Confirmation of these results in other populations, particularly those with a different 
profile of disease prevalence is needed.
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Introduction
Studies1–3 frequently use visual acuity assessment or questionnaires to screen for eye 
disease. Often these tests in isolation are inadequate to accurately and reliably detect eye 
disease.2,4,5 Other screening studies report results for a single condition such as diabetic eye 
disease or glaucoma.6–9 These approaches are limited in their comprehensive ability to 
identify those with other asymptomatic eye disease in a community-based screening.
Only limited work examines screening modalities for multiple ocular diseases. One such 
study in an adult, primarily black, internal medicine primary care population suggested a 
two step approach, first using a questionnaire to identify those at risk followed by referral 
for dilated examination.10 The prevalence of asymptomatic ocular disease within a 
population would be expected to vary the usefulness of a questionnaire as an initial 
screening tool. Another study found presenting visual acuity less than 20/40 was highly 
sensitive for eye disease, but was unable to identify an individual vision screening test that 
was both highly sensitive and specific for disease and they did not evaluate a combination of 
screening tests.11
Early identification and therapeutic intervention reduces the morbidity associated with 
ocular disease, particularly those without clinical symptoms in their early stages, such as 
glaucoma and diabetic retinopathy. Clinical studies, however, have yet to identify screening 
methods with high predictive values for identifying ocular disease in the general population. 
We assess the utility of employing a panel of ophthalmic screening techniques administered 
by an ophthalmic technician to identify participants with ocular disease and compare these 
results to a comprehensive eye examination by an onsite ophthalmologist. This study 
provides an opportunity to evaluate the predictive value of a panel of ophthalmic screening 
tests in a community-based study. Health care providers could use this testing paradigm to 
identify persons most likely to have eye disease and who would benefit from referral for 
comprehensive eye examination and treatment.
Methods
Study population
This study includes data from the previously published Tribal Vision Project12–15, a cross-
sectional eye disease prevalence study in American Indian and Alaskan Native participants. 
The current study is a validity assessment of a possible screening protocol. Briefly, we 
randomly selected American Indian and Alaskan Native participants from 3 tribes from the 
Northwest United States who were 40 years of age or older. All subjects had access to onsite 
medical care with ophthalmic care based on referral. We excluded participants with 
dementia or serious illness preventing travel to the clinic. We provided free transportation if 
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needed. The Portland Area Indian Health Service Institutional Review Board approved this 
study. All participants signed an informed consent prior to enrollment in the study.
Screening testing
Ophthalmic technicians performed an interview and examination consisting of a medical and 
ocular history, random finger stick blood glucose and glycosolated hemoglobin, automated 
refraction, tonometry (Tono-Pen XL, Medtronic Solan, Jacksonville, FL), slit lamp 
assessment of limbal anterior chamber depth16, frequency doubling technology perimetry 
(FDT, program C-20-5), confocal scanning laser ophthalmoscopy of the optic disc and 
peripapillary retina, and non-mydriatic digital imaging of the fundus and optic disc. 
Participants had normal FDT testing if results had no areas of abnormal sensitivity and the 
test was reliable (less than 33% fixation losses or false positives). Subjects underwent repeat 
FDT perimetry if the initial result for an eye was abnormal (at least one area of abnormal 
sensitivity) or unreliable (defined as over 33% fixation losses or false positives). If abnormal 
or unreliable results persisted on repeat testing, subjects were considered screening 
failures.17,18
Comprehensive eye examination by an ophthalmologist
Technicians referred subjects for a dilated, comprehensive exam by an onsite 
ophthalmologist if they had a personal history of glaucoma, retinopathy, macular 
degeneration, other eye abnormality or diabetes, a blood glucose >127 mg/dL or an 
A1C>5.7%. Subjects were also referred if one or both eyes had a best corrected visual acuity 
<20/40, intraocular pressure >21 mmHg, temporal limbal anterior chamber depth <25% of 
corneal thickness16, abnormal or unreliable FDT perimetry on initial and repeat testing18, 
borderline or abnormal Moorfield's regression or poor quality confocal scanning laser 
ophthalmoscopy19, or the presence of optic nerve, retinal or other eye disease on non-
mydriatic imaging or poor quality non-mydriatic digital imaging. If participants met the 
referral criteria in at least one eye, they were encouraged to have an exam. We also randomly 
selected 30% of subjects with normal screening results to have a dilated eye examination by 
an ophthalmologist to determine the predictive ability of passing all of the screening tests. 
The ophthalmologist was masked to the screening test results. The examination included slit 
lamp biomicroscopy of the anterior segment, gonioscopy, Lens Opacity Classification 
System III grading of the lens20, dilated fundus examination and perimetry testing (24-2 
Swedish interactive threshold algorithm standard, Humphrey Field Analyzer II, Carl Zeiss 
Meditech, Dublin, CA). The ophthalmologist used standard criteria for classification of 
ocular disease (Table 1). A separate ophthalmologist independently confirmed any 
abnormality found during the comprehensive eye exam by chart review of the patient history, 
testing results, and photographs of the optic disc and macula, and this result was used to 
define the presence or absence of eye disease.
Statistical testing
We calculated summary statistics, cross tabulations and binomial univariate logistic 
regression using R version 2.15.1. We compared the demographic characteristics using chi-
square or t-tests as applicable for those that did and did not complete the follow up 
examination.
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We used statistical weighting in R to determine the prevalence of eye diseases because not 
all of the participants completed the comprehensive exam with an ophthalmologist. We 
created weights by dividing the total number of normal screening exam results by the 
number of participants with normal screening exam results who completed the follow-up 
examination (120/20=6.0); and by dividing the total number of abnormal screening exam 
results by the number of participants with abnormal screening exam results who completed 
the follow-up examination (309/210=1.471).21
In contrast to the above analysis, we only used data from participants that completed the 
comprehensive eye exam for the predictive value of the screening tests. We used the logistic 
procedure in SAS 9.3 to determine the screening tests with significant univariate 
associations (p value <.05). Those with univariate associations were used as possible 
covariates for a multivariate model using a stepwise logistic regression procedure with a chi-
square significance level of .05 for entering and retaining a covariate in the final model. We 
calculated sensitivity, specificity, positive and negative predictive values using 2×2 tables for 
each individual screening test with the different eye diseases as well as for the 
comprehensive screening panel and those tests found associated with visually significant eye 
disease with any eye disease.
We used IBM SPSS statistics (version 21.0.0.0, Armonk, NY) to create a receiver operator 
curve to assess the diagnostic precision of detecting eye disease with the final multivariate 
subset of screening tests associated with eye disease. For this graph, we used the predictive 
values of a logistic regression equation with eye disease as the outcome of interest (1=yes, 
0=no eye disease) with 4 independent variables from the final multivariate model: visual 
acuity worse than 20/40, abnormal/poor quality non-mydriatic imaging, abnormal FDT 




Table 2 describes the demographic characteristics of the 429 participants. A significant 
proportion of the population was diabetic (20.0%) or had hypertension (31.9%). A prior 
history of eye disease was reported by 22.8% of subjects.
Table 3 shows the percentage of participants failing the individual screening parameters. Of 
the 429 participants, only 120 (28.0%) passed all of the screening tests. The most commonly 
failed screening test was FDT perimetry (195/429, 45.5%) making this the largest source of 
referral for further ophthalmic examination. Abnormal or poor quality confocal scanning 
laser ophthalmoscopy was also common in our cohort (146/429, 34.0%). As may be 
expected, subjects with a best corrected visual acuity <20/40 frequently had abnormal FDT 
(40/51, 78.4%). Only 36.3% (4/11) of subjects with an intraocular pressure > 21 mm Hg had 
an abnormal FDT.
Of the 309 subjects with abnormal screening tests, 210 (68.3%) completed the 
comprehensive follow up examination. The participants completing follow up examination 
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and those that did not were similar in gender, age, diabetes, hypertension or history of eye 
disease. However, subjects with a follow up examination were more likely to have failed 
confocal scanning laser ophthalmoscopy screening than their counterparts that did not 
follow up (52% vs. 38%, p<.05); there were no other differences in demographic 
characteristics or proportion of failed screening tests between the two groups. We also 
examined 20 out of 36 (20/36, 55.6%) subjects with normal screening results to provide a 
measure of specificity.
Table 4 displays the prevalence of eye disease. The most common diseases included age-
related macular degeneration, glaucoma, diabetic retinopathy, and other retinal disease. The 
ophthalmologists considered one participant with normal screening tests to have early age-
related macular degeneration based on drusen of the macula but had a best-corrected visual 
acuity of 20/20 in both eyes. We defined visually significant cataract only if their visual 
acuity was less than 20/40 and the cataract was felt to be the primary cause of the reduced 
acuity.
Association analysis
Table 5 shows the univariate logistic regression results of the screening tests for eye disease. 
Abnormal or poor quality non-mydriatic imaging was significantly associated with all eye 
diseases. As expected, diabetic retinopathy was associated with a personal history of 
diabetes and abnormal blood sugar or hemoglobin A1C. Intraocular pressure greater than 21 
mm Hg was uncommon. Age-related macular degeneration, the most common ocular 
disease in our cohort, was associated with visual acuity less than 20/40, abnormal or poor 
quality confocal scanning laser ophthalmoscopy, abnormal FDT and abnormal or poor 
quality non-mydriatic photography.
We used those screening tests significant (p <.05) in univariate analysis (Table 5) as 
candidate covariates for the multivariate model. Table 6 shows the results of the stepwise 
logistic regression to identify the best combination of screening tests to be associated with 
individual eye diseases and ‘any eye disease’. The multivariate analysis identified visual 
acuity worse than 20/40, abnormal or poor quality non-mydriatic photography, abnormal 
FDT, and abnormal or poor quality confocal scanning laser ophthalmoscopy to be associated 
with any eye disease (last column).
We calculated the sensitivity and specificity of the comprehensive screening panel as 99 and 
16% respectively. We found the positive predictive value of our comprehensive screening 
panel to be 53.3%. The negative predictive value was 95% because the ophthalmologist 
identified small drusen fitting the criteria for age-related macular degeneration in one subject 
with all normal screening tests. This participant demonstrated a best-corrected visual acuity 
of 20/20 in both eyes.
We were interested in how the subset of screening tests associated with any eye disease in 
multivariate analysis would perform, and re-classified subjects using only this subset of 
screening tests (visual acuity worse than 20/40, abnormal or poor quality non-mydriatic 
photography, abnormal FDT, and abnormal or poor quality confocal scanning laser 
ophthalmoscopy). Of the original 309 subjects failing at least one of the screening tests, 271 
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continued to be classified as screening failures using only the 4 screening tests listed above 
(63.2% of the original cohort, 271/429). For the 210 subjects with abnormal screening using 
the complete testing panel who then underwent a comprehensive exam, 186 continued to be 
classified as screening failures. Our analysis considered the remaining 24 (out of 210 
subjects) as passing screening, and only 7 of these subjects had eye disease on clinical 
examination (three with diabetic retinopathy, two with macular degeneration, and one with 
glaucoma). However, the three subjects with diabetic retinopathy had bilateral best-corrected 
visual acuities of 20/20 and only background diabetic retinopathy; and the two subjects with 
macular degeneration also had best corrected visual acuities of 20/20 in both eyes and only 
small retinal pigmented epithelial changes or small drusen in at least one eye. The subject 
designated as having glaucoma passed FDT screening and had normal intraocular pressure 
during the screening. However, the comprehensive eye exam demonstrated small peripheral 
defects with white-on-white standard automated perimetry and glaucomatous rim thinning in 
the left eye only. Overall, this suggests that the screening tests may have missed early stage 
diabetic retinopathy, glaucoma, and macular degeneration.
Table 7 describes the diagnostic precision of the comprehensive screening panel, 
comprehensive screening panel excluding FDT, and of the 4 screening tests (visual acuity 
worse than 20/40, abnormal or poor quality non-mydriatic photography, abnormal FDT, and 
abnormal or poor quality confocal scanning laser ophthalmoscopy) in the final multivariate 
model. The 4 screening tests had a sensitivity of 94%, and a specificity of 32%. The positive 
predictive value was 57%, and the negative predictive value was 84.1%. A receiver operating 
characteristic curve (Figure 1) had an area under the curve of .827 (.772, .882, 95% CI).
We also determined the sensitivity and specificity for the individual screening tests with eye 
disease (Supplemental material available at AJO.com). We did not find a single screening 
test to provide much diagnostic precision with the sensitivity of the individual screening 
tests ranging from 4% (intraocular pressure >21) to 74% (abnormal FDT), and similarly 
poor specificity. Overall, this suggests no single screening test has enough diagnostic 
precision to screen for eye disease. However, a subset of screening tests (visual acuity worse 
than 20/40, abnormal or poor quality non-mydriatic photography, abnormal FDT, and 
abnormal or poor quality confocal scanning laser ophthalmoscopy) may be useful.
Discussion
We examined a panel of screening tests for their utility in identifying subjects with ocular 
disease in a population of American Indians/Alaskan Natives. We determined that visual 
acuity less than 20/40, abnormal or poor quality non-mydriatic photography, abnormal FDT, 
and abnormal or poor quality confocal scanning laser ophthalmoscopy were predictive of 
visually significant eye disease. These tests showed high negative predictive value with rare 
misclassification of participants with early macular degeneration, glaucoma, or background 
diabetic retinopathy. It also showed a high proportion of eye disease in those with an 
abnormal test. This suggests that a subset of screening tests could provide a basis for 
community based ophthalmic screening.
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Our subset of screening tests associated with visually significant eye disease had a 
sensitivity of 94%, a specificity of 32%, a positive predictive value of 57%, a negative 
predictive value of 84% and a ROC curve of 82.7%. These results leave room for 
improvement. However, in identifying subjects with ocular disease, the screening tests 
missed only those with early macular degeneration or diabetic retinopathy with 20/20 vision 
and glaucoma with only early perimetric changes. One may argue that these missed diseases 
would not require treatment at this early stage and could be discovered at a later time. While 
the negative predictive value of our screening design was high, the lower positive predictive 
value of our screening exams may result in over referral of patients for further 
ophthalmology exams.
Prior community based eye disease screening programs have similar findings. A 
community-based screening program conducted by trained lay person screeners found 57% 
of those screened met one or more referral criteria.3 In another study of subjects recruited 
from an internal medicine clinic, 66.7% met at least one referral criteria during screening for 
a comprehensive eye examination10, similar to our findings here. As our screening paradigm 
was not tested in an independent validation sample, the predictive performance of our 
identified subset of screening tests may be less in other populations. Similarly, the predictive 
value of screening tests vary with the prevalence of disease within a population and 
alternative combinations of screening tests than those identified here may be more beneficial 
in communities with different disease burdens.
An advantage of our screening approach is the administration of tests by eye care 
paraprofessional (e.g. ophthalmic technicians), thus decreasing the burden of eye disease 
case finding by eye care providers. This approach also allowed for the utilization of 
ophthalmic technologies such as confocal scanning laser ophthalmoscopy and non-mydriatic 
fundus photos for screening; both tests proved useful in identifying eye disease in our 
population. Future studies need to examine methods to reduce false positive results to make 
the positive predictive value higher and decrease the burden of referral. Despite the 
possibility for over referral, our study identified a limited panel of ophthalmic screening 
tests that could be adapted for use in medically underserved communities without routine 
access to ophthalmic care to increase recognition of at risk members within the population.
A high rate of abnormal FDT screening contributed to our lower positive predictive value; a 
third of the patients with an abnormal screening test but no eye disease on comprehensive 
examination were those with an abnormal FDT. Others have identified a low positive 
predictive value with population based screening for glaucoma using FDT9,22,23; however, 
the potential greater sensitivity to early glaucomatous defects with FDT8 makes it appealing 
for screening. Additionally, FDT has shown utility in identifying diseases other than 
glaucoma24. Abnormal FDT testing has also been reported in diabetics.25 FDT normative 
databases did not include Native Americans and development of a normative database 
specific to this population may have improved performance.26 We used the C-20-5 FDT 
algorithm for screening, which presents stimuli at a contrast level that 95% of healthy age-
matched controls would be expected to detect; this screening algorithm is designed to have a 
higher sensitivity to detect early field defects at the expense of specificity. The use of an 
alternative screening algorithm, such as the C-20-1 program which uses stimuli at a contrast 
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level 99% of healthy age-matched controls should detect, could improve specificity, 
although the trade off in identifying patients with disease would need to be assessed.
The use of confocal scanning laser ophthalmoscopy in community based glaucoma 
screening is uncommon27–29; in these studies, confocal scanning laser ophthalmoscopy is 
moderately sensitive (61-85%) with a higher specificity (86-96%). In our population, we 
found confocal scanning laser ophthalmoscopy to have a similar sensitivity (75.7%) for 
glaucoma, with a slightly lower specificity (56.5%) to previous studies. To our knowledge, 
the current study is the first to incorporate screening with confocal scanning laser 
ophthalmoscopy with a combination of community based screening tests.
More than 20% of our study population was diabetic, a known risk factor for visual 
impairment.30 Our analysis identified a history of diabetes, abnormal blood sugar or 
hemoglobin A1C and abnormal non-mydriatic photos as associated with diabetic 
retinopathy, which re-emphasizes the usefulness of these screening modalities in monitoring 
for diabetic eye disease.31,32 Sensitivity and specificity estimates for diabetic retinopathy 
fundus photography range from 38-100% and 75-100% when compared with dilated 
ophthalmoscopy32, similar to the observed sensitivity of 65.2% and specificity of 76.5% in 
our cohort.
We offered participants a free, on-site comprehensive ophthalmology exam if they had an 
abnormal screening exam and random selection of those with normal testing. We provided 
gift cards, free transportation, childcare, and a work release with paid-time off to complete 
the examination. Despite this, some participants did not return for the full eye examination, 
including both those with abnormal screening results and those invited back who had normal 
screening results. However, the overall 60% rate of follow-up is very similar to results in 
prior community screening programs.3,33,34 Reasons for not returning were similar to 
previous studies3,33,34 and included lack of time for additional examination, a desire to avoid 
dilation, a second opinion from their local eye care provider, and not believing the results of 
screening.
Our study demonstrates the feasibility of identifying patients with visually significant eye 
disease in an American Indian/Alaskan Native population using commonly available 
screening techniques administered by ophthalmic technicians and suggests a combination of 
screening tests that may be most useful. The current U.S. Preventive Task Force 
recommendation on screening for primary open angle glaucoma in asymptomatic patients in 
the primary care setting concludes that there is currently insufficient evidence to assess the 
balance of benefits versus harms to screening.35 Perhaps screening studies to detect all eye 
disease (similar to the current study) would show benefits in limiting ocular morbidity. 
Future studies will need to be completed to assess the feasibility of implementation of such a 
program and its effects on visual health care outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Receiver operating characteristic curve relating the multivariate subset of screening tests 
(visual acuity < 20/40, abnormal or poor quality non-mydriatic imaging, abnormal frequency 
doubling technology perimetry, abnormal or poor quality confocal scanning laser 
ophthalmoscopy) to eye disease.
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Table 1
Case definitions of ocular diseases: Screening tests for visually significant eye disease.
Eye Disease Definition
Visually significant cataract Visual acuity ≤20/40 with lens opacities (LOCSIII score ≥2.0 for cortex, posterior subcapsular, nuclear or 
hypermature cataract) without another ocular explanation19
Glaucoma Presence of:
1 Cup-to-disc ratio ≥ 0.8 or glaucomatous features (rim thinning, excavation, nerve fiber 
defect) and glaucomatous visual field loss
2 Cup-to-disc ratio ≥ 0.8 or glaucomatous features (rim thinning, excavation, nerve fiber 
defect) and an inability to satisfactorily complete visual field testing
3 Subjects unable to complete visual field testing with optic discs unable to be viewed and 
IOP >2236
Diabetic retinopathy Presence of any non-proliferative retinopathy (microaneurysms, dot blot hemorrhages or intraretinal 
microvascular angiopathy), proliferative retinopathy (neovascularization with or without high risk 
characterization) or clinically significant macular edema37–39
Age-related macular degeneration Presence of soft drusen >125 microns, macular pigmentary changes, geographic atrophy or macular 
neovascularization not associated with other retinal disease40
Other retinal disease Additional retinal disease, such as prior retinal artery or vein occlusion or uveitic disease
Narrow angles No visible angle structures in two or more quadrants on gonioscopy36
Corneal disease Presence of any corneal disease, such as edema, scarring or neovascularization













Kopplin and Mansberger Page 14
Table 2
Demographic characteristics: Screening tests for visually significant eye disease. Data are presented as number 
(%) unless otherwise specified.
Characteristics N=429
Female gender 271 (63.2)
Age (Mean (SD), range in years) 55.7 (11.6), 40-88
Diabetic (history of diabetes, hemoglobin A1C > 5.7 or fasting blood glucose > 127) 86 (20.0)
Hypertensive (systolic blood pressure > 135 or diastolic blood pressure > 80) 137 (31.9)
Personal history of eye diseasea 98 (22.8)
a
Glaucoma, retinopathy, macular degeneration, other eye abnormality SD; standard deviation
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Table 3
Participants with abnormal results on initial screening tests administered by an ophthalmic technician: 
Screening tests for visually significant eye disease.
Ophthalmic Screening Test N=429a N (%)
Screening pass on all tests 120 (28.0)
History of eye disease or diabetes 98 (22.8)
Blood glucose >127 or HgbA1C >5.7 63 (14.7)
Visual acuity <20/40 51 (11.9)
Narrow limbal anterior chamber depth 49 (11.4)
Abnormal or poor quality CSLO 146 (34.0)
Abnormal FDT 195 (45.5)
Abnormal or poor quality non-mydriatic photo 92 (21.4)
Intraocular pressure > 21 mm Hg 11 (2.6)
a
Total numbers do not add to 429 because participants could be abnormal on multiple screening tests.
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Table 4
Prevalence of ocular disease with a comprehensive eye exam by an onsite ophthalmologist: Screening tests for 
visually significant eye disease.
Ocular Diseasea Number (%) N=230b
Corneal disease 8 (2.7)
Narrow angles 2 (0.7)
Visually significant cataract 11 (3.8)
Glaucoma 36 (12.5)
Diabetic retinopathy 23 (7.9)
Age-related macular disease 54 (19.6)
Other retinal disease 22 (8.5)
Any eye disease 113 (39.8)
Normal eye examination 117 (60.2)
a
Case definitions listed in Table 1
b
Numbers do not add to 230 because a participant could have more than one ocular disease. We used statistical weights of 1.471 for those with 
screening abnormal results and 6.0 for those with screening normal results (See Methods, Statistical analysis section) to calculate weighted 
prevalence percentages.20
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Table 7
Performance measures of screening tests in identifying eye disease: Screening tests for 
visually significant eye disease
Sensitivity Specificity PPV NPV
Comprehensive screening panel 99% 16% 53% 95%
Comprehensive screening panel excluding FDT 93% 35% 58% 84%
Screening tests associated with eye disease in the final multivariate modela 94% 32% 57% 84%
N=230. PPV; positive predictive value; NPV; negative predictive value; FDT; frequency doubling technology perimetry
a
Visual acuity worse than 20/40, abnormal or poor quality non-mydriatic photography, abnormal frequency doubling technology perimetry, and 
abnormal or poor quality confocal scanning laser ophthalmoscopy
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